Immunodynamics of explanted human tumors for immuno-oncology.
cancer
immune checkpoint inhibitors
immunomonitoring
precision oncology
“in sitro” assay
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380
Informations de publication
Date de publication:
11 01 2021
11 01 2021
Historique:
received:
30
05
2020
revised:
26
10
2020
accepted:
28
10
2020
pubmed:
30
12
2020
medline:
6
10
2022
entrez:
29
12
2020
Statut:
ppublish
Résumé
Decision making in immuno-oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex functional and dynamic immuno-assay based on the capacity of the TME to respond to ex vivo stimulation with twelve immunomodulators including immune checkpoint inhibitors (ICI) in 43 human primary tumors. This "in sitro" (in situ/in vitro) assay has the potential to predict unresponsiveness to anti-PD-1 mAbs, and to detect the most appropriate and personalized combinatorial regimen. Prospective clinical trials are awaited to validate this in sitro assay.
Identifiants
pubmed: 33372722
doi: 10.15252/emmm.202012850
pmc: PMC7799366
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12850Informations de copyright
© 2020 The Authors. Published under the terms of the CC BY 4.0 license.
Références
Oncoimmunology. 2016 Jun 30;5(9):e1204507
pubmed: 27757299
Nat Rev Immunol. 2020 Jan;20(1):25-39
pubmed: 31570880
Cell. 2015 Apr 9;161(2):185-6
pubmed: 26042237
Cancer Cell. 2018 Apr 9;33(4):649-663.e4
pubmed: 29576375
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Clin Cancer Res. 2016 Nov 15;22(22):5461-5471
pubmed: 27169994
Nat Med. 2019 Oct;25(10):1549-1559
pubmed: 31591606
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
Nat Commun. 2020 Jan 30;11(1):602
pubmed: 32001684
Nat Commun. 2017 Sep 19;8(1):592
pubmed: 28928380
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762
pubmed: 30361681
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Sci Transl Med. 2017 Sep 13;9(407):
pubmed: 28904226
EMBO Mol Med. 2021 Jan 11;13(1):e12850
pubmed: 33372722
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Nat Med. 2020 May;26(5):688-692
pubmed: 32405062
Front Immunol. 2018 Nov 26;9:2728
pubmed: 30534127
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008
pubmed: 31028147